The effect of folic acid throughout pregnancy among pregnant women at high risk of pre-eclampsia: A randomized clinical trial.
Pregnancy Hypertens
; 19: 253-258, 2020 Jan.
Article
in En
| MEDLINE
| ID: mdl-31987769
ABSTRACT
BACKGROUND:
Pre-eclampsia is a serious hypertension disease that occurs during pregnancy. Folic acid (FA) supplementation has been reported to reduce pre-eclampsia risk in pregnant women. Here, we aimed to assess whether treatment of high doses of FA in pregnant women with high pre-eclampsia risk could prevent the onset of pre-eclampsia.METHODS:
We conducted a randomized clinical trial in 1576 women who had pre-eclampsia or eclampsia in their last pregnancy and had a pregnancy plan. Subjects were randomized into two groups. The low dose (LD) group (n = 788) received 0.4 mg of FA daily from the first 3 months of pregnancy until the entire pregnancy, and the high dose (HD) group (n = 788) received 4 mg of FA per day. We followed up the subjects until production.RESULTS:
The plasma homocysteine (homocysteine) and FA levels were significantly higher in the HD group that in the LD group. Severe gestational hypertension, early onset pre-eclampsia (<32 weeks' gestation), severe pre-eclampsia, and newborns' Apgar score <7 at 5 min were remarkably decreased in the HD group compared with the LD group. Further, the incidence of pre-eclampsia was reduced in the HD group with compliance >50%.CONCLUSION:
This study has provided evidence that a high dosage of FA supplement from 3 months before pregnancy until the entire pregnancy reduces the recurrent pre-eclampsia.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Pre-Eclampsia
/
Vitamin B Complex
/
Secondary Prevention
/
Folic Acid
Type of study:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Language:
En
Journal:
Pregnancy Hypertens
Year:
2020
Type:
Article
Affiliation country:
China